We have located links that may give you full text access.
English Abstract
Journal Article
[Chinese experts consensus on the treatment of metastatic prostate cancer 2018 edition].
Zhonghua Wai Ke za Zhi [Chinese Journal of Surgery] 2018 September 2
The prevalence of prostate cancer has shown a marked increase in China. Most patients are presented with metastasis at diagnosis.It has been proven by clinical trials that besides androgen deprivation therapy, Abiraterone and docetaxel can improve the overall survival of metastatic hormone sensitive prostate cancer patients with high risks.For metastatic castration-resistant prostate cancer treatment, docetaxel, abiraterone and enzalutamide, etc., have demonstrated significant overall survival benefit. Among them, docetaxel and abiraterone have accumulated adequate experience in Chinese patients. Therefore, it is quite important for Chinese physicians to make reasonable clinical decisions based on these treatment regimes. In order to improve patients' survival and life quality, Chinese Anticancer Association Genitourinary Oncology Committee composed this expert consensus to help physicians to make reasonable decisions.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app